About Interpace Biosciences
Interpace Biosciences is a company based in Parsippany Troy Hills (United States) founded in 1986. The company has 94 employees. Interpace Biosciences offers products and services including PancraGEN, ThyGeNEXT, and ThyraMIR. Interpace Biosciences operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Parsippany Troy Hills, United States
- Employees 94
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website interpace.com
- Social LinkedIn Facebook
- Legal Name Interpace Biosciences, Inc.
- Annual Revenue$46.93 M (USD)17as on Dec 31, 2024
- Net Profit$6.7 M (USD)0as on Dec 31, 2024
- EBITDA$8.11 M (USD)105as on Dec 31, 2024
- Latest Funding Round$47M (USD), Post-IPO
Oct 2024
- Investors1315 Capital
& 1 more
- Employee Count94
Products & Services of Interpace Biosciences
Interpace Biosciences offers a comprehensive portfolio of products and services, including PancraGEN, ThyGeNEXT, and ThyraMIR.
Assesses risk of pancreatic cyst cancer for early detection.
Evaluates thyroid nodules to guide treatment decisions.
Complements thyroid testing for improved accuracy in diagnostics.
Funding Insights of Interpace Biosciences
- Total Rounds 4
- Last Round Post-IPO — $47M
- First Round $111,150
(Jan 2017)
- Investors Count 2
All 4 funding rounds of Interpace Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $47M | Post-IPO | – | – | – |
| Jan 2020 | $20M | Post-IPO | – | – | |
| Oct 2017 | $5M | Post-IPO | – | – | – |
| Jan 2017 | $111,150 | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Interpace Biosciences
Interpace Biosciences has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include 1315 Capital and Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Expansion and growth capital is provided by 1315 Capital to healthcare companies. | – | 1315capital.com | Philadelphia, United States | |
Ampersand Capital Partners is focused on investments in healthcare and life sciences. | – | ampersandcapital.com | Boston, United States |
Investor details for Interpace Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Interpace Biosciences
32 people are tracked at Interpace Biosciences (8 in leadership, 5 in board & advisors, 19 in team); the tracked headcount is 94.
| Name | Role | Group |
|---|---|---|
Thomas Burnell | CEO & President | Leadership |
William Pink | Senior Director of Corporate Disbursements | Leadership |
Syd Finkelstein | Chief Scientific Officer, Interpace Diagnostics | Leadership |
Christina M. Narick | VP, Pathology & Director Barretts Program, Interpace Diagnostics | Leadership |
Rob Renjilian | Chief Commercial Officer | Leadership |
Ginette Halvorsen | Human Resources Director | Leadership |
Christopher McCarthy, CPA | Chief Financial Officer & Chief Operating Officer | Leadership |
Janelle McLaughlin | Vice President Of Sales Endocrine Division | Leadership |
Ron Rocca | Director | Board & advisors |
Edward Chan | Director | Board & advisors |
Robert Gorman | Chairman | Board & advisors |
Joseph Keegan | Director | Board & advisors |
Stephen J. Sullivan | Director | Board & advisors |
Heather Saad | National Strategic Account Manager | Team |
Michelle B. | Senior Business Account Manager, Fl, Sc, Ga, Nc, AL | Team |
John Berry | Senior Regional Sales Manager | Team |
Lisa R Adams | Executive Regional Account Manager | Team |
Cristine Baratta | Account Manager | Team |
Marianne Butterworth | Regional Account Executive | Team |
Sam Jerome | Sr. Executive Regional Account Manager | Team |
12 more people are available in the full profile.
Complete people profiles for Interpace Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Interpace Biosciences
4 dated milestones of Interpace Biosciences across 38 years, from founding to its latest funding, stage changes and deals.
- Founded Interpace Biosciences is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $111K.
- Funding Latest funding round, Post-IPO, of $47.0M.
Competitors of Interpace Biosciences
Interpace Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection | |
| billiontoone.com | 2015 | San Francisco, United States | $388.62M | 47 | Provider of cell-free cancer liquid biopsy test |
Detailed competitors of Interpace Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Interpace Biosciences
The website of Interpace Biosciences (interpace.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 13.4% vs previous month
Latest news on Interpace Biosciences
Complete news archive for Interpace Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Interpace Biosciences
10 companies that operate in the same segment as Interpace Biosciences (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Interpace Biosciences
Interpace Biosciences was founded in 1986 and raised its 1st funding round 31 years after it was founded.
Interpace Biosciences is headquartered in Parsippany Troy Hills, United States. It is registered at Parsippany Troy Hills, New Jersey, United States.
Thomas Burnell is the current CEO of Interpace Biosciences.
Interpace Biosciences has 94 employees.
Annual revenue of Interpace Biosciences is $46.93M as on Dec 31, 2024.
Founded in 1986 and headquartered in Parsippany Troy Hills, United States, operations in the healthcare sector are focused on molecular diagnostics for cancer. Evidence-based tests for early detection and treatment guidance are offered, along with pathology services. These solutions support clinical decision-making in oncology, with services delivered through a network addressing gastrointestinal, thyroid, and pancreatic cancers.
Interpace Biosciences's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Interpace Biosciences offers PancraGEN, ThyGeNEXT, and ThyraMIR.
Interpace Biosciences has 2 investors. Key investors include 1315 Capital, and Ampersand Capital Partners.
Interpace Biosciences operates through Interpace Biosciences, Inc..